Document Detail

Progress in the treatment of bone metastases in cancer patients.
MedLine Citation:
PMID:  22500564     Owner:  NLM     Status:  MEDLINE    
INTRODUCTION: Bone metastases are a frequent complication of cancer, occurring in up to 70% of patients with advanced breast or prostate cancer. Skeletal-related events involving pathological fractures, spinal cord compression and a need for surgery/radiotherapy, which are frequently observed in cancer patients with bone metastases have a detrimental effect on patients' survival and quality of life. Therefore, prevention of skeletal-related events is a crucial element in cancer treatment.
AREAS COVERED: The aim of this article was to summarize data on bone-modifying agents used for treatment of cancer patients with bone metastases. We searched PubMed, EMBASE, and abstracts from ASCO, AUA, ESMO, AACR congresses for clinical studies evaluating bone-modulating agents in the treatment of patients with bone metastases.
EXPERT OPINION: In breast cancer patients with bone metastasis, several bisphosphonates and denosumab demonstrated clinical efficacy. On the other hand, in patients with bone metastases from prostate cancer or other solid tumors only zoledronic acid and denosumab were clinically active. However, neither bisphosphonates nor denosumab have any positive impact on survival of patients with bone metastases. In a recent interim analysis of a Phase III clinical study, a novel bone-modulating agent - radium-223 chloride (alpharadin), a bone-seeking alpha emitter, has been demonstrated to significantly improve median overall survival of prostate cancer patients with bone metastases compared with placebo.
Malgorzata Mackiewicz-Wysocka; Magdalena Pankowska; Piotr J Wysocki
Related Documents :
11490224 - Lymphatic mapping and detection of sentinel nodes in patients with bladder cancer.
2544924 - Biliary carcinoma: ct evaluation of extrahepatic spread.
16412604 - Evaluation of sentinel node identification with isosulfan blue in gastric cancer.
20583444 - Extreme analysis of risk factors for lymph node metastasis in gastric cancer.
22561374 - Targeted silencing of the oncogenic transcription factor sox2 in breast cancer.
24511244 - The incidence rate of corpus uteri cancer among females in saudi arabia: an observation...
Publication Detail:
Type:  Journal Article; Review     Date:  2012-04-16
Journal Detail:
Title:  Expert opinion on investigational drugs     Volume:  21     ISSN:  1744-7658     ISO Abbreviation:  Expert Opin Investig Drugs     Publication Date:  2012 Jun 
Date Detail:
Created Date:  2012-05-14     Completed Date:  2012-09-07     Revised Date:  2013-11-06    
Medline Journal Info:
Nlm Unique ID:  9434197     Medline TA:  Expert Opin Investig Drugs     Country:  England    
Other Details:
Languages:  eng     Pagination:  785-95     Citation Subset:  IM    
University of Medical Sciences, Department of Dermatology, Poznan, Poland.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Alpha Particles / therapeutic use
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Bone Density Conservation Agents / therapeutic use
Bone Neoplasms / drug therapy*,  secondary,  therapy
Breast Neoplasms / pathology*
Diphosphonates / therapeutic use
Prostatic Neoplasms / pathology*
Quality of Life
Radium / therapeutic use
Survival Rate
Reg. No./Substance:
0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Bone Density Conservation Agents; 0/Diphosphonates; 4EQZ6YO2HI/denosumab; 7440-14-4/Radium

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Chrominance to Dimension: a Rapid and Real-time Method for Measuring the Size of Single Gold Nanopar...
Next Document:  Morphological and morphometric study of the opossum's dorsal root ganglia neurons.